{"title":"部分交叉设计在早期随机预防试验中的应用","authors":"Alan D. Hutson , Mary E. Reid","doi":"10.1016/j.cct.2004.07.005","DOIUrl":null,"url":null,"abstract":"<div><p>In this note, we outline the benefits of a partial cross-over design for a class of experiments where the interest is the cumulative effect of dose versus placebo. The goal of our design strategy is to answer several complex question efficiently in a phase II setting with a minimal number of assumptions with an eye towards planning a phase III study.</p></div>","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"25 5","pages":"Pages 493-501"},"PeriodicalIF":0.0000,"publicationDate":"2004-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cct.2004.07.005","citationCount":"15","resultStr":"{\"title\":\"The utility of partial cross-over designs in early phase randomized prevention trials\",\"authors\":\"Alan D. Hutson , Mary E. Reid\",\"doi\":\"10.1016/j.cct.2004.07.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>In this note, we outline the benefits of a partial cross-over design for a class of experiments where the interest is the cumulative effect of dose versus placebo. The goal of our design strategy is to answer several complex question efficiently in a phase II setting with a minimal number of assumptions with an eye towards planning a phase III study.</p></div>\",\"PeriodicalId\":72706,\"journal\":{\"name\":\"Controlled clinical trials\",\"volume\":\"25 5\",\"pages\":\"Pages 493-501\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.cct.2004.07.005\",\"citationCount\":\"15\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Controlled clinical trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0197245604000698\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Controlled clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0197245604000698","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The utility of partial cross-over designs in early phase randomized prevention trials
In this note, we outline the benefits of a partial cross-over design for a class of experiments where the interest is the cumulative effect of dose versus placebo. The goal of our design strategy is to answer several complex question efficiently in a phase II setting with a minimal number of assumptions with an eye towards planning a phase III study.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
